InsiderTrades

Form 4 for ADMA ADMA BIOLOGICS, INC.

Accepted 2023-03-08 00:00:00 ET · period of report 2023-02-25 · accession 0001140361-23-010774 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-03-08 2023-02-25+ ADMA Grossman Adam S Pres, CEO, Dir F - Tax $3.43 -49.5K 2.01M -2% -$169.9K
D 2023-03-08 2023-03-06 ADMA Grossman Adam S Pres, CEO, Dir A - Grant $0.00 +573.7K 2.58M +29% $0
D 2023-03-08 2023-03-06 ADMA Grossman Adam S Pres, CEO, Dir A - Grant $0.00 +1.15M 1.15M New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-25 F D 4,018 $3.42 2,032,823 D — —
2 Common Common Stock 2023-02-25 F D 14,412 $3.42 2,018,411 D — —
3 Common Common Stock 2023-03-07 F D 23,607 $3.40 2,560,992 D — — (F2) (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (F3) (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,179,206 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. (F4) These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
4 Common Common Stock 2023-03-06 A A 573,695 $0.00 2,584,599 D — — (F1) Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 453,750 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;
5 Common Common Stock 2023-02-28 F D 7,507 $3.55 2,010,904 D — —
6 Derivative Employee Stock Option (right to buy) 2023-03-06 A A 1,147,385 $0.00 1,147,385 D $3.35 · — to 2033-03-06 1,147,385 Common Stock (F6) The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027.